Novavax, Inc.
A maker of protein-based vaccines against infectious diseases, this Maryland biotech is best known for Nuvaxovid, its COVID-19 shot that delivers pre-made spike proteins grown in moth cells rather than genetic instructions. Founded in 1987 and spun off from its parent IGI in 1995, it gained its Matrix-M immune-boosting adjuvant by buying Sweden's Isconova in 2013. The name blends "nova" (new) with "vax" (vaccine).
Sold 3.00M
Bought 358.8K
Bought 35.2K
Sold 10.00M
Granted 483.1K
Sold 231.6K
Bought 100.0K
Granted 135.5K
Granted 100.0K · Sold 208.8K
Granted 189.8K
Bought 42.6K
Granted 200.0K · Bought 11.7K · Sold 258.3K
Bought 90.5K
Granted 100.0K · Bought 14.7K · Sold 34.7K
Granted 125.3K
Sold 1.74M
Granted 303.4K · Bought 159.0K · Sold 151.9K
Granted 39.8K · Sold 25.0K
Granted 45.7K · Bought 550.0K
Granted 79.4K · Sold 61.2K
Bought 14.9K
Granted 112.5K · Bought 426.5K · Sold 387.3K
Granted 47.7K
Granted 47.4K
Granted 44.5K
Granted 43.2K · Bought 86.7K · Sold 4.2K
Bought 67.3K · Sold 28.7K
Granted 739.0K · Bought 353.1K · Sold 715.4K
Granted 372.9K · Bought 230.8K · Sold 967.2K
Bought 1.0K · Sold 15.0K
Granted 20.3K
Bought 20.6K
Granted 10.0K · Bought 20.0K
Bought 3.8K · Sold 8.3K
Granted 404.1K · Bought 133.1K · Sold 454.1K
Granted 228.3K · Bought 27.4K · Sold 211.0K
Granted 14.3K
Granted 10.0K · Sold 10.0K
Granted 152.2K · Bought 77.6K · Sold 15.9K
Granted 9.5K
Granted 7.9K
Granted 25.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Cadila Pharmaceuticals Ltd +1 co-filer10% owner · 3 transactions | — | 9.50Mas of Mar 2014 | — | — | 3.00M |
| Monath Thomas PDirector · 2 transactions | — | 3.23Mas of Jul 2008 | — | 358.8K | — |
| Tananbaum James BDirector · 1 transaction | — | 3.15Mas of Jul 2008 | — | 35.2K | — |
| Modi Rajiv I.Director · 17 transactions | — | 2.50Mas of Jun 2015 | — | — | 10.00M |
| Jacobs John CPresident and CEO, Director · 10 transactions | — | 225.7K | 483.1K | — | — |
| Odonnell Denis MDirector · 2 transactions | — | 221.5Kas of Mar 2006 | — | — | 231.6K |
| Boudreaux GailDirector · 1 transaction | — | 200.0Kas of Sep 2016 | — | 100.0K | — |
| O'Hara ElaineEVP, Chief Strategy Officer · 8 transactions | — | 157.1K | 135.5K | — | — |
| Hage Raymond JosephSr. VP. Commercial Operations · 23 transactions | — | 140.2Kas of Jul 2009 | 100.0K | — | 208.8K |
| Kelly James PatrickEVP, CFO and Treasurer · 22 transactions | — | 130.6K | 189.8K | — | — |
| Robinson JimVP, Tech. & Quality Operations · 4 transactions | — | 113.7Kas of Jul 2008 | — | 42.6K | — |
| Singhvi RahulPresident, CEO, Director · 16 transactions | — | 113.1Kas of Jul 2009 | 200.0K | 11.7K | 258.3K |
| Hahn Timothy JonSVP, Manufacturing · 8 transactions | — | 110.5Kas of Jan 2015 | — | 90.5K | — |
| Lambert John ADirector · 11 transactions | — | 105.9Kas of Jul 2009 | 100.0K | 14.7K | 34.7K |
| Casey Mark JEVP, Chief Legal Officer · 8 transactions | — | 101.4K | 125.3K | — | — |
| Kelly Mitchell JDirector · 2 transactions | — | 95.5Kas of Mar 2006 | — | — | 1.74M |
| Trizzino JohnPresident and COO · 256 transactions | — | 82.0Kas of Mar 2025 | 303.4K | 159.0K | 151.9K |
| Mott David MDirector · 10 transactions | — | 79.8K | 39.8K | — | 25.0K |
| Douglas RichardDirector · 15 transactions | — | 73.2K | 45.7K | 550.0K | — |
| Dubovsky FilipPresident, R&D · 18 transactions | — | 66.6Kas of Jun 2024 | 79.4K | — | 61.2K |
| Wilson Russell PSVP, Business Development · 3 transactions | — | 64.9Kas of Jan 2015 | — | 14.9K | — |
| Young James FDirector · 34 transactions | — | 51.8Kas of Dec 2024 | 112.5K | 426.5K | 387.3K |
| Alton Gregg HDirector · 9 transactions | — | 47.7K | 47.7K | — | — |
| Rodgers Richard JDirector · 6 transactions | — | 47.4K | 47.4K | — | — |
| McGlynn Margaret GDirector · 9 transactions | — | 44.5K | 44.5K | — | — |
| King Rachel K.Director · 11 transactions | — | 44.1K | 43.2K | 86.7K | 4.2K |
| Phillips Barclay ASVP, Chief Financial Officer · 14 transactions | — | 38.7Kas of Jul 2017 | — | 67.3K | 28.7K |
| Erck Stanley CPresident and CEO, Director · 128 transactions | — | 36.5Kas of Dec 2022 | 739.0K | 353.1K | 715.4K |
| Evans Gary CDirector · 32 transactions | — | 36.3Kas of Jun 2021 | 372.9K | 230.8K | 967.2K |
| Johnston Thomas ScottVice President, Strategy · 3 transactions | — | 23.8Kas of Jul 2009 | — | 1.0K | 15.0K |
| Hall PatriciaChief Accounting Officer · 6 transactions | — | 21.0Kas of Oct 2006 | 20.3K | — | — |
| Stigliano Len FVP, CFO, Treasurer · 2 transactions | — | 20.6Kas of Jul 2008 | — | 20.6K | — |
| Driscoll Frederick WVP, CFO & Treasurer · 2 transactions | — | 20.0Kas of Aug 2011 | 10.0K | 20.0K | — |
| Heaton PennyVP & Chief Medical Officer · 4 transactions | — | 18.7Kas of Jul 2009 | — | 3.8K | 8.3K |
| Glenn Gregory MPresident, R&D · 483 transactions | — | 18.3Kas of Mar 2023 | 404.1K | 133.1K | 454.1K |
| Herrmann John A IIIEVP, Chief Legal Officer · 247 transactions | — | 17.3Kas of Dec 2023 | 228.3K | 27.4K | 211.0K |
| Draghia-Akli RuxandraSection 16 · 2 transactions | — | 14.3K | 14.3K | — | — |
| Lazarus J Michael MDDirector · 2 transactions | — | 11.9Kas of Dec 2005 | 10.0K | — | 10.0K |
| McManus Michael A JrDirector · 19 transactions | — | 10.1Kas of Jun 2022 | 152.2K | 77.6K | 15.9K |
| Newton Charles W.Director · 1 transaction | — | 9.5K | 9.5K | — | — |
| Shiver John W.Director · 1 transaction | — | 7.9K | 7.9K | — | — |
| Genge Dennis WVP, Treasurer,CFO · 1 transaction | — | 6.4Kas of Feb 2006 | 25.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -15.70M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.